Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette’s Disorder with Clonidine Extended Release
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
We aimed to assess the effectiveness and safety of clonidine extended release (ER) treatment in Korean youth with ADHD and/or Tourette’s disorder. We retrospectively reviewed the medical records of 29 children and adolescents treated with clonidine ER. The effectiveness were retrospectively measured at baseline and after 4 and 12 weeks based on the Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety was evaluated at each visit based on spontaneous reports from the subjects or from their parents/guardians. Significant decreases in the CGI-S scores for both ADHD (F=23.478, p<0.001, partial η2=0.540) and tic symptoms (F=15.137, p<0.001, partial η2=0.443) were noted over 12 weeks. The most common adverse event was somnolence (n=9, 31.0%) and life-threatening adverse effects were not observed. Our results provide preliminary evidence for the effectiveness and safety of clonidine ER.
Abstract
We aimed to assess the effectiveness and safety of clonidine extended release (ER) treatment in Korean youth with ADHD and/or Tourette’s disorder. We retrospectively reviewed the medical records of 29 children and adolescents treated with clonidine ER. The effectiveness were retrospectively measured at baseline and after 4 and 12 weeks based on the Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety was evaluated at each visit based on spontaneous reports from the subjects or from their parents/guardians. Significant decreases in the CGI-S scores for both ADHD (F=23.478, p<0.001, partial η2=0.540) and tic symptoms (F=15.137, p<0.001, partial η2=0.443) were noted over 12 weeks. The most common adverse event was somnolence (n=9, 31.0%) and life-threatening adverse effects were not observed. Our results provide preliminary evidence for the effectiveness and safety of clonidine ER.
참고문헌 (10)
- Hirota T, "Alpha-2 agonists for attention-deficit", hyperactivity disorder in youth: a systematic review and metaanalysis of monotherapy and add-on trials to stimulant therapy, 2014, pp.53, 153~173
- Schwartz S, "Efficacy and safety of atomoxetine in children and adolescents with attention-deficit", hyperactivity disorder: results from a comprehensive meta-analysis and metaregression, 2014, pp.53, 174~187
- Faraone SV, "Using Meta-analysis to compare the efficacy of medications for attention-deficit", hyperactivity disorder in youths, 2009, pp.34, 678~694
- Ganos C, "Tics and tourette syndrome", Neurol Clin, 33, pp.115~136 (2015)[DOI]
- Jiao F, "Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch", Eur J Paediatr Neurol, 20, pp.80~84 (2016)[DOI]
- Cavanna AE, "Tolerability profile of clonidine in the treatment of adults with Tourette syndrome", Clin Neuropharmacol, 35, pp.269~272 (2012)[DOI]
- Jain R, "Clonidine extended-release tablets for pediatric patients with attention-deficit", hyperactivity disorder, 2011, pp.50, 171~179
- Kollins SH, "Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD", Pediatrics, 127, pp.e1406~e1413 (2011)[DOI]
- Leckman JF, "Clonidine treatment of Gilles de la Tourette's syndrome", Arch Gen Psychiatry, 48, pp.324~328 (1991)[DOI]
- Kessler AR, "Clonidine treatment increases tics in patients with Tourette syndrome: case report", J Child Neurol, 16, pp.380~381 (2001)[DOI]